Synthesis of Thieno[2,3-d]oxazines and Thieno[2,3-d]thiazines as Subtype Specific Kainate Receptor Antagonists
For the development of new antiepileptics the kainate receptors, GluR6 and GluR5, are important targets. Based on the anticonvulsant effects of chinazolines and thieno[2,3-d]pyrimidines that are known from the literature, thieno[2,3-d][1.3]oxazines were synthesized and studied for their inhibitory properties at GluR6 and GluR5 receptors. The strongest inhibitor activity was observed with 5-methyl-6-phenyl-thieno[2,3-d][1.3]oxazines with C1 or C3-substituents in position 2 (3b-f). The 2-trihalide-methyl-substituted compounds 3c and 3d were the most active inhibitors at the GluR5- receptor (IC50=23.4 μmol, 16 μl). The 2-isopropyl-substituted compound 3f displayed the strongest activity at the GluR6- receptor (IC50=8.7 μmol). A number of thieno[2,3-d][1.3]thiazines and thieno[2,3-d]pyrimidines that were synthesized from the thieno[2,3][1.3]oxazines did not show any activity.
Keywords: Glutamate receptor antagonists; anticonvulsives; kainate receptor antagonists; thieno[2,3-d]-pyrimidines; thieno[2,3-d][1.3]oxazines; thieno[2,3-d][1.3]thiazines
Document Type: Research Article
Affiliations: Institute of Pharmacy, Faculty of Biosciences, Pharmacy and Psychology, University of Leipzig, Bruderstraße 34, 04103 Leipzig, Germany.
Publication date: 01 December 2009
- Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.
- Editorial Board
- Information for Authors
- Subscribe to this Title
- Ingenta Connect is not responsible for the content or availability of external websites
- Access Key
- Free content
- Partial Free content
- New content
- Open access content
- Partial Open access content
- Subscribed content
- Partial Subscribed content
- Free trial content